“Buy” Rating Was Issued By Broker For Portola Pharmaceuticals (NASDAQ:PTLA)

Share

How Goldman Sachs Currently Rates Portola Pharmaceuticals (NASDAQ:PTLA)

Goldman Sachs issued “Buy” rating on Portola Pharmaceuticals (NASDAQ:PTLA). The firm have started coverage on shares of PTLA in an analyst note shared with investors on Friday morning.

Approximately 794,086 shares of stock traded hands or 52.60% up from the average. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 35.55% since May 15, 2015 and is uptrending. It has outperformed by 39.36% the S&P500.

The overall sentiment of institutions has decreased to 1.5 in Q2 2015. Its down 0.03, from 1.53 in 2015Q2. The ratio dived, as 11 institutions have sold all the shares of Portola Pharmaceuticals Inc that they owned while 49 funds have taken shares off the table. 25 funds have purchased shares for the first time while 65 added to their positions. These institutions now hold 46.01 million shares or 4.38% less than the 48.12 million shares they owned in 2015Q2.

The Fund Redmile Group Llc currently is holding shares equating to 8.26% of its total portfolio in Portola Pharmaceuticals Inc representing a total of 769,641 shares. Another fund,Mpm Asset Management Llc, is holding a total of 1.22 million shares equating to 8% of their holdings. Additionally, Fernwood Investment Management Llc has a 190,011 share stake in Portola Pharmaceuticals Inc which represents 7.1% of their total portfolio. The Fund, Cormorant Asset Management Llc, based out of Massachusetts, has also built up a stake in the stock, which represents a total of 3.4% of their total portfolio. Finally Harvey Capital Management Inc, a fund which is based in the state of Florida reported a total holdings of 157,930 shares.

Insider activity is a very important aspect to track on any stock. Going back to April 30, 2015, shareholders of Portola Pharmaceuticals Inc have witnessed 0 insider purchases, and a total of 9 insider sales equating to a net activity of approximately $15.03 million . Dier Mardi sold 8,912 shares worth approximately $490,160. Homcy Charles J sold 40,067 shares worth approximately $2.25 million. Curnutte John T sold 10,000 shares worth approximately $500,000. Lis William sold 50,000 shares worth approximately $2.50 million. The company insider Renton Hollings sold 10,520 shares worth $403,179.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.86 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

According to Zacks Investment Research, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.”

COMMENTS: